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| INTRODUCTION
Sulphonylureas (SUs) are conventionally chosen as the treatment for type 2 diabetes mellitus (T2DM) after metformin failure 1 ; however, the glucoselowering effect of SUs tends to diminish as a function of time. Dipeptidyl peptidase-4 (DPP-4) inhibitors, a novel class of OADs that function to inhibit the DPP-4 enzyme-induced degradation of glucagon-like peptide-1, have become a widely accepted option for T2DM treatment in the past decade. 2 Regarding the long-term efficacy of DPP-4 inhibitors for glycaemic control, although a recent meta-analysis combining the results of longterm clinical trials suggested that the effect of DPP-4 inhibitors on glycated haemoglobin (HbA1c) levels in patients with T2DM may decline during the second year of treatment, 3 conclusive results have not been obtained.
More importantly, the results of pilot studies evaluating the comparative glycaemic durability of DPP-4 inhibitors and SUs were not consistent [4] [5] [6] [7] [8] [9] [10] [11] ; therefore, the aim of the present study was to perform a meta-analysis of 
| METHODS
This meta-analysis was performed in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 12 and the Cochrane Handbook guidelines. 13 and significant heterogeneity was considered if P < .10. The I 2 statistic was determined to describe the percentage of total variation across studies. A random effects model was used because it is a more conservative method which considers heterogeneity among the included studies. 13 Data from studies with more than one interventional arm with DPP-4 inhibitors were considered as multiple comparisons and were included in the meta-analysis after the sample sizes of the control groups had been equally split, as indicated by the Cochrane Handbook guideline. 13 Publication bias was assessed by visual inspection of the asymmetry of the funnel plot and Egger's regression asymmetry test. 13 P values were two-tailed, and statistical significance was set at P < .05.
| Statistical analysis
3 | RESULTS
| Study selection
A flow chart outlining the study selection process is presented in Figure S1 . A final total of eight RCTs were included in our study.
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| Study characteristics and quality evaluation
Of the eight included RCTs, one included two interventional arms with different doses of alogliptin (12.5 and 25 mg once daily), and these were included as two comparisons. The clinical and baseline patient characteristics for the included studies are presented in Table 1 . All of the RCTs included patients already taking metformin, except for one study that included medication-naïve patients, 4 and there was considerable variation in HbA1c levels at baseline (7.5%-11.0%). Different DPP-4 inhibitors were used, including vildagliptin, sitagliptin, alogliptin, linagliptin and saxagliptin. The drop-out rate was substantial for the included RCTs, and the strategies of considering observed cases and last observation carried forward were applied to handle this issue. The details of the quality evaluation are shown in Table S1 . All of the included studies were double-blind RCTs.
| Comparative glycaemic durability of DPP-4 inhibitors and SUs
Treatment with DPP-4 inhibitors was associated with significantly smaller changes in HbA1c levels from 24 to 28 weeks to 104 weeks (MD −0.16%, 95% CI −0.21 to −0.11; P < .001; Figure 1A ) and 52 weeks to 104 weeks (MD −0.06%, 95% CI −0.10 to −0.02; P = .001; Figure 1B ) compared with SUs, with no considerable heterogeneity (I 2 = 0%). A sensitivity analysis based on the omission of the study including medication-naïve patients showed similar results (24-28 weeks: MD −0.15%, 95% CI −0.20 to −0.10, P < .001; 52 weeks: MD −0.06%, 95% CI −0.10 to −0. 02, P = .003).
| Publication bias
The funnel plots for the comparative effectiveness of DPP-4 inhibitors and SUs for long-term glycaemic control ( Figure S2 ) were symmetrical on visual inspection, suggesting no significant publication bias. Egger's significance test also did not indicate the existence of publication bias (P = .542 and P = .388, respectively).
| DISCUSSION
The present meta-analysis showed that treatment of patients with early study in rats with streptozotocin-induced diabetes found that the DPP-4 inhibitor P32/98 had a dose-dependent preventive effect on streptozotocin-induced β-cell apoptosis, suggesting that the therapeutic effects of DPP-4 inhibitors may involve the prevention of functional β-cell loss. 17 By contrast, treatment with glipizide, was not associated with restoration of β-cell mass. 18 Subsequent experimental studies also indicated that some DPP-4 inhibitors had protective effects on β-cell mass and function. 19 These results suggest that the preservation of β-cell mass and function is a common effect of DPP-4 inhibitors. Further studies are needed to confirm our hypothesis that DPP-4 inhibitors confer better protective effects on β-cell mass and function in humans, particularly as compared with SUs.
Our results have limitations that should be considered when interpreting the results. First, we tested our hypothesis that DPP-4 inhibitors offer better glycaemic durability than SUs using the change in the to studies originally designed with a 104-week follow-up produced similar results. Fifthly, the participant drop-out rates varied among the RCTs, which may have influenced the quality of the study. Finally, although no significant statistical heterogeneities were observed among the included RCTs, these studies varied with regard to the study and patient characteristics.
In conclusion, long-term treatment with DPP-4 inhibitors conferred better glycaemic control compared with SUs in patients with T2DM, which may reflect that DPP-4 inhibitors better preserve islet β-cell function than do SUs.
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